Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies

被引:32
作者
Rezaei, Nima
Aghamohammadi, Asghar
Siadat, Seyed Davar
Nejati, Mehdi
Ahmadi, Hojat
Moin, Mostafa
Pourpak, Zahra
Kamali, Samineh
Norouzian, Dariush
Tabaraei, Bahman
Read, Robert C.
机构
[1] Univ Sheffield, Sch Med & Biomed Sci, Sect Infect Inflammat & Immun, Sheffield, S Yorkshire, England
[2] Inst Pasteur, Dept Bacterial Vaccine & Antigen Prod, Tehran, Iran
[3] Med Sci Univ Tehran, Immunol Asthma & Allergy Res Inst, Children Med Ctr, Dept Allergy & Clin Immunol, Tehran 14194, Iran
关键词
antibody response; meningococcal disease; polysaccharide vaccine; primary antibody deficiencies; serum bactericidal antibody assay;
D O I
10.1016/j.vaccine.2007.05.021
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2 +/- 3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A + C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P < 0.001) and the control group (12.13 versus 1.26, P < 0.001). All controls had a protective SBA response (SBA titre of >= 8 post-vaccination or rise of >= 4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P = 0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5308 / 5314
页数:7
相关论文
共 43 条
[1]   Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency [J].
Aghamohammadi, A ;
Farhoudi, A ;
Moin, M ;
Rezaei, N ;
Kouhi, A ;
Pourpak, Z ;
Yaseri, N ;
Movahedi, M ;
Gharagozlou, M ;
Zandieh, F ;
Yazadni, F ;
Arshi, S ;
MohammadZadeh, I ;
Ghazi, BM ;
Mahmoudi, M ;
Tahaei, S ;
Isaeian, A .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (07) :825-832
[2]   Primary immunodeficiency in Iran: First report of the national registry of PID in children and adults [J].
Aghamohammadi, A ;
Moein, M ;
Farhoudi, A ;
Pourpak, Z ;
Rezaei, N ;
Abolmaali, K ;
Movahedi, M ;
Gharagozlou, M ;
Ghazi, BMS ;
Mahmoudi, M ;
Mansouri, D ;
Arshi, S ;
Trash, NJ ;
Akbari, H ;
Sherkat, R ;
Hosayni, RF ;
Hashemzadeh, A ;
Mohammadzadeh, I ;
Amin, R ;
Kashef, S ;
Alborzi, A ;
Karimi, A ;
Khazaei, H .
JOURNAL OF CLINICAL IMMUNOLOGY, 2002, 22 (06) :375-380
[3]  
AGHAMOHAMMADI A, 2000, IRAN J ALLERGY ASTHM, V1, P135
[4]   Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia [J].
Aghamohammadi, Asghar ;
Fiorini, Maurilia ;
Moin, Mostafa ;
Parvaneh, Nima ;
Teimourian, Shahram ;
Yeganeh, Mehdi ;
Goffi, Francesca ;
Kanegane, Hirokazu ;
Amirzargar, Ali Akbar ;
Pourpak, Zahra ;
Rezaei, Nima ;
Salavati, Ali ;
Pouladi, Nima ;
Abdollahzade, Sina ;
Notarangelo, Luigi D. ;
Miyawaki, Toshio ;
Plebani, Alessandro .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2006, 141 (04) :408-414
[5]   Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England [J].
Andrews, N ;
Borrow, R ;
Miller, E .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (05) :780-786
[6]  
BELL WE, 1992, PEDIATR CLIN N AM, V39, P651
[7]   Update on primary immunodeficiency diseases [J].
Bonilla, FA ;
Geha, RS .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) :S435-S441
[8]   Meningococcal surrogates of protection - serum bactericidal antibody activity [J].
Borrow, R ;
Balmer, P ;
Miller, E .
VACCINE, 2005, 23 (17-18) :2222-2227
[9]  
Borrow R, 2000, FEMS IMMUNOL MED MIC, V28, P79, DOI 10.1111/j.1574-695X.2000.tb01460.x
[10]  
BRUTON OC, 1952, PEDIATRICS, V9, P722